clinical trial · NCT07650916
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
ViiV Healthcare·phase3·not yet recruiting·n = 564
HIV InfectionsCAB ULARPV ULACAB LARPV LA
brief summary
This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).
started
Jun 29, 2026
primary completion
Sep 4, 2029
completion
Sep 4, 2029
last updated
Jun 16, 2026
official title
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents With HIV Who Are Virologically Suppressed on ART
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol